AGIO - Agios Pharmaceuticals Inc Stock Price, Fair Value and News

28.71USD-0.72 (-2.45%)Delayed as of 19 Apr 2024, 03:02 pm ET

Market Summary

USD28.71-0.72

Delayedas of 19 Apr 2024, 03:02 pm

-2.45%

AGIO Alerts

1 major insider sales recently.

AGIO Stock Price

View Fullscreen

AGIO RSI Chart

AGIO Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-4.7

Price/Sales (Trailing)

57.35

EV/EBITDA

-4.45

Price/Free Cashflow

-5.57

AGIO Price/Sales (Trailing)

AGIO Profitability

EBT Margin

-1221.04%

Return on Equity

-43.41%

Return on Assets

-37.57%

Free Cashflow Yield

-17.96%

AGIO Fundamentals

AGIO Revenue

Revenue (TTM)

28.8M

Rev. Growth (Yr)

-18.85%

Rev. Growth (Qtr)

-31.19%

AGIO Earnings

Earnings (TTM)

-352.1M

Earnings Growth (Yr)

-362.66%

Earnings Growth (Qtr)

-5.05%

Breaking Down AGIO Revenue

52 Week Range

21.6430.26

(Low)(High)

Last 7 days

-3.9%

Last 30 days

-2.2%

Last 90 days

35.4%

Trailing 12 Months

28.4%

How does AGIO drawdown profile look like?

AGIO Financial Health

Current Ratio

12.27

AGIO Investor Care

Shares Dilution (1Y)

2.10%

Diluted EPS (TTM)

-6.34

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	19.7M	26.1M	30.0M	28.8M
2022	94.1M	66.8M	39.6M	12.3M
2021	0	175.9M	148.6M	121.4M
2020	174.8M	184.3M	193.7M	203.2M
2019	115.9M	101.7M	112.5M	117.9M
2018	41.3M	70.3M	74.2M	94.4M
2017	49.1M	53.5M	55.9M	43.0M
2016	70.7M	64.5M	68.0M	69.9M
2015	62.0M	66.9M	38.4M	44.6M
2014	27.7M	29.8M	57.5M	65.4M
2013	25.1M	25.1M	25.1M	25.5M
2012	22.7M	23.5M	24.3M	25.1M
2011	0	0	0	21.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Agios Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 10, 2024	fouse jacqualyn a	sold	-214,642	27.55	-7,791	-
Apr 08, 2024	fouse jacqualyn a	acquired	-	-	15,934	-
Mar 07, 2024	foster-cheek kaye i	sold	-40,631	31.62	-1,285	-
Mar 06, 2024	foster-cheek kaye i	sold	-141,236	31.99	-4,415	-
Mar 05, 2024	burns james william	sold	-86,049	32.57	-2,642	chief legal officer
Mar 05, 2024	goff brian	sold	-135,361	32.57	-4,156	chief executive officer
Mar 05, 2024	washburn theodore james jr.	sold	-39,540	32.57	-1,214	principal accounting officer
Mar 05, 2024	jones cecilia	sold	-21,887	32.57	-672	chief financial officer
Mar 05, 2024	washburn theodore james jr.	sold	-60,737	31.75	-1,913	principal accounting officer
Mar 05, 2024	foster-cheek kaye i	sold	-9,663	32.21	-300	-

Which funds bought or sold AGIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	AdvisorNet Financial, Inc	sold off	-100	-34,118	-	-%
Apr 05, 2024	CWM, LLC	added	6.96	1,000	5,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	336	1,155	1,404	-%
Apr 05, 2024	NBC SECURITIES, INC.	new	-	8,000	8,000	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	55.18	2,933	10,333	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.09	-12,226,700	123,096,000	-%
Mar 05, 2024	Fisher Asset Management, LLC	reduced	-12.96	-4,385,550	15,845,600	0.01%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	50.96	7,142,990	27,077,600	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	-71,245	614,875	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	new	-	2,319,000	2,319,000	0.20%

Are Funds Buying or Selling AGIO?

Are funds buying AGIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AGIO

No. of Funds

AGIO Alerts

1 major insider sales recently.

Unveiling Agios Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	6.31%	3,524,000	SC 13G/A
Feb 14, 2024	rock springs capital management lp	3.85%	2,152,173	SC 13G/A
Feb 13, 2024	bb biotech ag	7.2%	4e+06	SC 13G/A
Feb 12, 2024	vanguard group inc	10.02%	5,599,917	SC 13G/A
Feb 12, 2024	vanguard group inc	9.89%	5,527,438	SC 13G/A
Feb 08, 2024	farallon capital partners, l.p.	0.6%	350,343	SC 13G/A
Jan 25, 2024	blackrock inc.	8.9%	4,962,237	SC 13G/A
Jan 22, 2024	state street corp	4.70%	2,625,685	SC 13G/A
Nov 09, 2023	farallon capital partners, l.p.	0.6%	332,366	SC 13G
Nov 09, 2023	wellington management group llp	3.95%	2,200,757	SC 13G/A

Recent SEC filings of Agios Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading
Mar 07, 2024	144	Notice of Insider Sale Intent
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 06, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading

Peers (Alternatives to Agios Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.0B	6.8B	-2.93%	-28.56%	-8.27	5.69	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-2.14%	-28.32%	-41.48	9.99	76.23%	61.08%
BMRN	17.0B	2.4B	5.64%	-9.07%	101.38	7.03	15.42%	18.43%
INCY	11.9B	3.7B	-9.46%	-28.45%	19.84	3.21	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-16.55%	-42.15%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-12.14%	49.76%	-6.72	60.35	54.84%	-34.79%
AXSM	3.1B	270.6M	-14.48%	-8.88%	-13.01	11.51	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.72%	-14.74%	-45.89	3.87	40.45%	71.62%
ARWR	2.8B	240.7M	-18.65%	-25.84%	-9.44	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.41%	-11.48%	25.32	4.54	85.90%	-14.05%
NVAX	544.4M	983.7M	-21.26%	-56.58%	-1	0.55	-50.36%	17.16%
CRBP	382.8M	881.7K	-14.69%	262.26%	-8.58	466.16	-77.61%	-5.33%
INO	238.4M	4.9M	-4.49%	-3.41%	-1.76	48.98	-54.97%	51.71%
IBIO	6.2M	2.1M	67.92%	36.92%	-0.23	2.14	-13.45%	66.37%

Agios Pharmaceuticals Inc News

Latest updates

Agios Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	-31.2%	5,091,000	7,399,000	8,254,000	8,091,000	6,273,500	3,516,000	1,793,000	694,000	475,000	256,000	22,150,500	44,045,000	1,115,000	44,106,500	87,098,000	35,440,000	26,024,000	26,221,000	30,227,000	30,013,000	15,198,000
Costs and Expenses	4.7%	113,380,000	108,296,000	100,412,000	96,222,000	103,482,000	94,606,000	103,222,000	101,977,000	104,827,000	91,152,000	91,222,000	85,332,000	80,290,000	83,264,000	87,030,000	-86,607,000	135,084,000	140,082,000	127,710,000	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	135,084,000	140,082,000	127,710,000	126,369,000	114,360,000
S&GA Expenses	36.7%	35,305,000	25,822,000	30,409,000	28,367,000	32,771,000	29,123,000	28,264,000	31,515,000	31,528,000	27,152,000	29,215,000	25,908,500	28,347,000	29,178,000	31,672,000	4,807,000	33,019,000	32,390,000	31,791,000	31,858,000	31,104,000
R&D Expenses	-5.3%	77,489,000	81,841,000	68,895,000	67,301,000	70,298,000	64,966,000	74,523,000	70,123,000	73,299,000	64,000,000	62,007,000	59,423,500	51,943,000	54,086,000	55,358,000	-90,384,000	101,672,000	107,389,000	95,585,000	93,809,000	82,561,000
EBITDA Margin	-Infinity%	-12.21	-	-8.53	-11.33	-18.15	-1.71	-1.71	-1.71	-1.71	-1.64	-1.62	-1.58	-	-	-	-	-	-	-	-	-
Income Taxes	-102.2%	-17,000	785,000	801,000	-	-1,940,000	98,000	-	1,842,000	7,162,000	2,716,000	6,200,000	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	33,832,000	-	-	-	-98,584,000	-84,259,000	-82,790,000	-84,541,000	-79,175,000	-81,495,000	-84,094,000	-	-	-	-	-	-
EBT Margin	-Infinity%	-12.21	-	-8.87	-11.78	-18.88	-1.75	-1.75	-1.75	-1.75	-1.69	-1.66	-1.62	-	-	-	-	-	-	-	-	-
Net Income	-5.1%	-95,940,000	-91,324,000	-83,806,000	-81,018,000	36,526,000	-81,747,000	-91,806,000	-94,774,000	-94,627,000	-88,766,000	-86,217,000	-97,657,000	-98,979,000	-90,478,000	-40,256,000	-102,350,000	-106,173,000	-109,871,000	-93,078,000	-91,794,000	-94,664,000
Net Income Margin	-66.9%	-12.21	-7.32	-8.04	-11.08	-18.88	-1.79	-1.82	-1.79	7.90	7.88	7.83	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-17.3%	-72,722,000	-62,012,000	-66,745,000	-95,582,000	-66,276,000	-71,389,000	-76,155,000	-100,539,000	-88,595,000	-85,162,000	-117,543,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-7.0%	937	1,007	1,085	1,151	1,239	1,180	1,252	1,336	1,438	1,541	1,875	2,488	853	908	976	800	891	699	784	822	858
Current Assets	18.4%	834	704	757	792	833	785	870	975	1,064	1,305	1,703	2,355	637	669	846	587	612	490	534	557	614
Cash Equivalents	37.1%	88.00	64.00	85.00	104	139	122	89.00	80.00	203	400	969	1,888	127	105	296	89.00	81.00	82.00	84.00	103	71.00
Inventory	10.4%	19.00	17.00	16.00	11.00	8.00	5.00	4.00	2.00	-	-	-	-	15.00	11.00	11.00	10.00	7.00	6.00	5.00	2.00	1.00
Net PPE	-8.4%	15.00	17.00	20.00	21.00	23.00	25.00	27.00	29.00	29.00	25.00	27.00	29.00	31.00	33.00	34.00	34.00	31.00	24.00	23.00	24.00	24.00
Liabilities	4.7%	126	120	121	115	138	130	128	128	146	147	153	192	453	428	418	174	250	250	251	202	171
Current Liabilities	16.3%	68.00	58.00	55.00	45.00	63.00	54.00	48.00	46.00	60.00	58.00	61.00	97.00	94.00	70.00	64.00	70.00	93.00	92.00	90.00	81.00	94.00
Shareholder's Equity	-8.5%	811	887	964	1,037	1,101	1,050	1,124	1,207	1,292	1,395	1,722	2,297	400	480	558	625	641	448	533	620	688
Retained Earnings	-13.2%	-822	-726	-635	-551	-470	-507	-425	-333	-238	-144	-55.37	31.00	-1,843	-1,745	-1,646	-1,556	-1,516	-1,413	-1,307	-1,197	-1,104
Additional Paid-In Capital	0.6%	2,437	2,422	2,411	2,399	2,386	2,375	2,362	2,351	2,334	2,322	2,306	2,266	2,243	2,226	2,204	2,182	2,156	1,862	1,840	1,818	1,794
Shares Outstanding	0.1%	56.00	56.00	56.00	56.00	55.00	55.00	55.00	55.00	60.00	57.00	61.00	70.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,558	-	-	-	1,200	-	-	-	3,268	-	-	-	3,280	-	-	-	2,563	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-17.6%	-72,488	-61,643	-66,748	-95,183	-66,163	-71,351	-74,229	-97,735	-84,093	-85,184	-117,294	-120,749	-49,397	-68,207	-67,797	-105,358	-93,611	-85,589	-88,151	-103,271	-74,187
Share Based Compensation	52.2%	13,814	9,076	11,737	10,139	11,465	11,156	11,165	15,510	11,621	12,148	14,885	14,854	13,341	14,977	17,614	15,670	2,807	18,588	18,547	18,108	18,187
Cashflow From Investing	142.8%	95,513	39,341	47,125	57,596	82,951	104,070	82,813	-26,573	-94,419	-232,731	-298,149	1,874,077	71,396	-126,244	22,459	108,135	-184,773	80,381	64,480	131,352	-12,805
Cashflow From Financing	-55.0%	847	1,882	237	2,467	22.00	1,187	-67.00	1,208	-18,586	-250,985	-503,458	7,261	582	3,448	252,103	5,385	277,606	3,337	3,808	4,860	1,016
Buy Backs	-	-	-	-	-	-	-	-	-	19,048	254,391	-	-	-	-	-	-	-	-	-	-	-

AGIO Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenue	$ 26,823	$ 14,240	$ 0
Operating expenses
Cost of sales	2,881	1,704	0
Research and development	295,526	279,910	256,973
Selling, general and administrative	119,903	121,673	121,445
Total operating expenses	418,310	403,287	378,418
Loss from operations	(391,487)	(389,047)	(378,418)
Gain on sale of contingent payments	0	127,853	0
Royalty income from gain on sale of oncology business	0	9,851	6,639
Interest income, net	33,344	12,793	836
Other income, net	6,055	6,749	14,433
Net loss from continuing operations	(352,088)	(231,801)	(356,510)
Net income from discontinued operations, net of tax	0	0	1,961,225
Net (loss) income	$ (352,088)	$ (231,801)	$ 1,604,715
Net loss from continuing operations per share - basic (in usd per share)	$ (6.33)	$ (4.23)	$ (5.90)
Net loss from continuing operations per share - diluted (in usd per share)	(6.33)	(4.23)	(5.90)
Net income from discontinued operations per share - basic (in usd per share)	0	0	32.45
Net income from discontinued operations per share - diluted (in usd per share)	0	0	32.45
Net (loss) income per share - basic (in usd per share)	(6.33)	(4.23)	26.55
Net (loss) income per share - diluted (in usd share)	$ (6.33)	$ (4.23)	$ 26.55
Weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net (loss) income per share – basic (in shares)	55,651,487	54,789,435	60,447,346
Weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net (loss) income per share – diluted (in shares)	55,651,487	54,789,435	60,447,346
Product revenue, net
Revenues:
Total revenue	$ 26,823	$ 11,740	$ 0
Milestone revenue
Revenues:
Total revenue	$ 0	$ 2,500	$ 0

AGIO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 88,205	$ 139,259
Marketable securities	688,723	643,860
Accounts receivable, net	2,810	2,206
Inventory	19,076	8,492
Prepaid expenses and other current assets	35,021	38,955
Total current assets	833,835	832,772
Marketable securities	29,435	313,874
Operating lease assets	54,409	65,129
Property and equipment, net	15,382	22,987
Other non-current assets	4,057	3,956
Total assets	937,118	1,238,718
Current liabilities:
Accounts payable	9,780	18,616
Accrued expenses	43,167	30,350
Operating lease liabilities	15,008	13,663
Total current liabilities	67,955	62,629
Operating lease liabilities, net of current portion	56,988	71,996
Other non-current liabilities	1,156	3,279
Total liabilities	126,099	137,904
Commitments and contingent liabilities (Note 16)
Stockholders’ equity:
Preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.001 par value; 125,000,000 shares authorized; 72,161,489 shares issued and 55,945,078 outstanding at December 31, 2023 and 71,256,118 shares issued and 55,039,707 outstanding at December 31, 2022	72	71
Additional paid-in capital	2,436,523	2,386,325
Accumulated other comprehensive loss	(441)	(12,535)
Accumulated deficit	(822,649)	(470,561)
Treasury stock, at cost (16,216,411 shares at December 31, 2023 and December 31, 2022)	(802,486)	(802,486)
Total stockholders’ equity	811,019	1,100,814
Total liabilities and stockholders’ equity	$ 937,118	$ 1,238,718

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Brian M. Goff M.B.A.
WEBSITE	agios.com
INDUSTRY	Biotechnology
EMPLOYEES	389

Agios Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Agios Pharmaceuticals Inc? What does AGIO stand for in stocks?

AGIO is the stock ticker symbol of Agios Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agios Pharmaceuticals Inc (AGIO)?

As of Thu Apr 18 2024, market cap of Agios Pharmaceuticals Inc is 1.65 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGIO stock?

You can check AGIO's fair value in chart for subscribers.

What is the fair value of AGIO stock?

You can check AGIO's fair value in chart for subscribers. The fair value of Agios Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Agios Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Agios Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AGIO is over valued or under valued. Whether Agios Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Agios Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGIO.

What is Agios Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, AGIO's PE ratio (Price to Earnings) is -4.7 and Price to Sales (PS) ratio is 57.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Agios Pharmaceuticals Inc's stock?

In the past 10 years, Agios Pharmaceuticals Inc has provided -0.033 (multiply by 100 for percentage) rate of return.